Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move
(NYSE: $ACB) (TSX: $ACB.TO) (TSXV: $EMH.V) (TSX: $ALEF.TO) (CSE: $CSI.C) (OTC: $TSOI)
(CSE: $AGRO.C)
Delta, Kelowna, BC –July 15,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07151ACB-EMH-ALEF-CSI-TSOI-AGRO.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “potcasts”,
looking at cannabis news, stocks to watch as well as insights from thought
leaders and experts.
In today’s podcast we look at a few early
announcements.
Aurora Cannabis Inc. (NYSE:
ACB) (TSX:
ACB) announced that
it has received Health Canada licenses for outdoor cultivation at two Canadian
sites.
The
new sites in Quebec and British Columbia will be used for cultivation research
to develop new technology, genetics and intellectual property in order to drive
sustainable, high-quality outdoor production. Aurora purposefully chose the
outdoor sites because they represent two different growing environments. The
company will conduct research on cultivation techniques to further excel at
growing cannabis in varying climate conditions and will examine approaches to
environmentally sustainable cannabis agriculture.
The
newly-named Western facility will be called Aurora Valley and is a 207-acre
operation in Westwold, British Columbia. The Eastern facility, a 21,000 square
foot operation at the Aurora Eau facility in Lachute, is the first approved
outdoor grow operation for cannabis in Quebec. Aurora Valley is expected to be
planted shortly and Aurora Eau has already been planted.
The
two sites are an extension of the scientific research Aurora will be conducting
at its new Comox facility, which will be ready in the fall of 2019. The Comox
facility consists of a 21,000 square foot indoor grow facility and a 10,500
square foot laboratory. This unique research centre will be home for Aurora's
plant breeding team designed to create new cannabis cultivars with improved
growing characteristics for both indoor and outdoor cultivation.
"Aurora
believes in innovative operations and intensive research and we're applying our
approach to outdoor grown cannabis," said Aurora CEO Terry Booth.
"Our team plans to use these areas to ensure we are able to consistently
grow the high-quality cannabis Aurora has become known for around the world.
We're proud to be a Canadian company and this is a further commitment to
research and job creation in Canada."
Dr.
Jonathan Page, Chief Science Officer at Aurora added, "For this season and
next, our focus will be on researching cultivation methods and evaluating
genetics in order to produce high THC and CBD cannabis in outdoor-grown plants,
with the ultimate goal of extracting these components. The unique climates of
each site also presents a great opportunity to determine which cultivars will
perform best in different outdoor environments."
In addition
to the two new outdoor production sites, Aurora confirms it has now received
the Health Canada processing license for its Aurora Air facility located near
the Edmonton International Airport and Aurora Sky. Aurora Air will be home to
several of the new production lines for edible products such as gummies and
chocolates, to be introduced to the Canadian consumer market in December 2019.
Emerald Health Therapeutics, Inc. (TSXV:
EMH) (OTCQX:
EMHTF) has
received its cultivation license from Health
Canada for the 12-acre outdoor grow area at its new organic cannabis operation
in Metro Vancouver, BC. The outdoor grow area is expected to be capable of
producing approximately 10,000 kg of cannabis annually with multiple crops
during a full growing season. With this license effective as of July 12, 2019,
Emerald is positioned to deliver one harvest and a portion of the expected full
production volume this year.
The 12
acres (~500,000 square feet) of outdoor cultivation are part of an overall
20-acre site that includes 156,000 sq. ft. in two greenhouses. This operation
was purposefully designed for organic cultivation with the goal of exceeding
20,000 kg of annual production. There is also the prospect of securing and
licensing an additional adjacent 12 acres of outdoor grow area, with potential
for an additional approximately 10,000 kg of annual production.
“As
one of the few licensed producers licensed for outdoor growing, receiving this
cultivation license highlights our planning and execution to achieve
potentially very-low cost organic cannabis. We have been working for months on
ground and seed preparation and are now preparing for planting,” said Dr. Avtar
Dhillon, Executive Chairman and President of Emerald. “With our team’s
extensive organic farming experience and expertise, we look forward to
assessing multiple cannabis strains and refining cultivation practices for
scalable outdoor growing.”
With
the organic operation’s first greenhouse ready for cultivation and the second
greenhouse near completion, Emerald will continue to apply for license
amendments to expand its licensed cultivation areas. Emerald is also working to
complete the requirements for municipal permitting.
Separately,
Health Canada also approved Emerald’s amendment application to increase its
processing footprint at one of its two Victoria, British Columbia facilities,
allowing Emerald to expand processing and storage capabilities.
Aleafia Health Inc. (TSX:
ALEF) (OTC:
ALEAF) announced that
on July 12, 2019, Aleafia Health’s wholly-owned subsidiary, Aleafia Farms Inc.,
secured a License Amendment under Health Canada’s Cannabis Regulations
authorizing cannabis cultivation for the entirety of the Company’s Port Perry
Outdoor Grow facility. The Licence immediately increases the Company’s licensed
and operational outdoor cultivation area from 292,000 sq. ft. to over 1.1
million sq. ft.
As previously announced on June 10, 2019,
Aleafia Farms received approval for cultivation in Zone 1 of the Outdoor Grow
facility, and days later completed the planting of Canada’s first legal,
large-scale outdoor crop. The License now adds Zones 2, 3 and 4 which
encompasses the full 1.1 million sq. ft. cultivation area. The License is
effective as of July 12, 2019 and expires on October 13, 2020.
The Company expects to commence planting
the newly licensed area on July 15, 2019, using approximately 7,000 cannabis
plants currently growing in pots in Zone 1. The Outdoor Grow operation will be
overseen by Aleafia Health’s proven, experienced cultivation team, which
together have led the build-out and operations of seven cannabis cultivation
facilities.
“The immediate four-fold increase in
Aleafia Health’s licensed and operational cultivation area is our most
significant milestone to date,” said Aleafia Health Chairman Julian Fantino.
“We will continue to lead the way in low-cost production. This exponentially
increases our total cultivation footprint while securing and increasing product
supply for medical cannabis patients.”
It is intended that the cannabis grown at
the Company’s Outdoor Grow facility will be processed at the Company’s Paris
Facility, for the extraction and production of high-margin products within a
closed loop ecosystem.
“Our team is again relentlessly focused
on execution, with plants in the ground within one business day of receiving
our new Health Canada licence,” said Aleafia Health CEO Geoffrey Benic. “We
plan to benefit from the increasing scale of our production operations across
three facilities. Low-cost cannabis grown at Port Perry will accelerate and
scale our mission of growing, producing and selling high-margin value-added
cannabis health and wellness products globally.”
Chemesis International Inc. (CSE:
CSI) (OTC:
CADMF) announced a
Partnership with U.S. based Happy Tea,
a brand of CBD infused sachets and shots, to expand its product offering and
realize cost savings by leveraging Chemesis’ extraction, finished goods
manufacturing and retail distribution.
Happy
Tea currently offers 3 products including powdered drink mixes and flavoured
oil shots that are comprised of a blend of all-natural ingredients,
antioxidants and are infused with 10mg of CBD.
Consumers can purchase these products individually or subscribe to
monthly deliveries, which are shipped via the company’s e-commerce sales
channels across the United States. Happy Tea will leverage Chemesis’
multi-state operations to increase production capabilities and create retail
brick and mortar exposure through the Companies distribution.
Chemesis
will assist Happy Tea in expanding its current 3 SKU’s to an expanded product
line of 9 SKU’s. The Company will manufacture Happy Tea products in its U.S.
based facilities and will increase production as demand rises. As per the
Partnership, Chemesis received a $4,000,000 USD minimum purchase order to
manufacture products, as demand rises and Happy Tea expands its product
catalogue, additional contracts will be added to ensure sufficient supply.
"The
production and development capabilities of Chemesis fits in-line with what
we’re are always striving to accomplish,” said Jarrod Swanger, COO of Happy
Tea. “Every CBD company on the block along with their manufacturers are making
creams and drops. We are the only two entities striving to redefine delivery.
With their capacity and capability and our branding we will own the CBD
market."
“We
are extremely pleased to be working with Happy Tea, a developed brand that is
currently in a high-growth phase,” said CEO, Edgar Montero. “Happy Tea’s
products and vision are something the Company believes in and excited to be
supporting its long-term growth. Both Companies are exploring other strategic
ways of working together to create mutual synergies that are beneficial to all
stakeholders. Chemesis’ will continue its efforts in creating lasting
partnerships that bring strong revenues and continued progression.”
Agrios Global Holdings Ltd. (CSE:
AGRO) (OTCQB:
AGGHF) announced that
Onyx Agronomics has substantially reduced their carbon footprint, cutting their
energy consumption by 63% and achieving greater yield efficiency by following
the growing recommendations made by the Company.
Agrios collects millions of unique data
points from the crops over the course of the harvest cycle on a per cultivar
basis, and then analyzes this "actionable data" in order to develop
effective strategies for optimizing the growing environment and reducing the
use of energy, light, and water. Thus, crops are raised sustainably in an
environmentally friendly way at a reduced cost.
On the advice of Agrios, the plant
density in the growing space is modified and a substantial increase in
flower-to-trim ratio has been observed. A simple modification in plant
placement increased crop yield efficiency from a 50.5% / 49.5% flower-to-trim
ratio to an 81% / 19% flower-to-trim ratio. This results in a higher volume of
premium product – an increased yield efficiency at lowered production costs,
and increased profitability.
Andrew Lange, Chief Technical Officer,
reports that, "Overall production or raw yield doesn't tell the complete
story on how a given company is set up to perform financially. There are also
several ways to measure crop yield, and some are more effective than others.
The most common yield reporting system is grams per square foot (g/sq. ft.) so
yields at different facilities can be compared based on productivity. The
square footage of the facility is calculated using the canopy of the
cultivation area, and product weight should be reported as dry and
destemmed."
However, there are no industry
regulations or monitoring of how a yield measurement is calculated amongst
commercial operators at the present time. There is variance in what is measured
as "canopy" space, and product weight could be of an inconsistent
product mix.
Lange believes that achieving production
and yield efficiency is more important than maximizing raw yield, for several
reasons. Large cannabis cultivation facilities have increased operational cost
and risk. While such facilities' raw yield may be greater, their production
costs are also higher. Companies such as Agrios which have developed production
efficiencies and consume less energy or are otherwise environmentally friendly,
and have a smaller carbon footprint, are also spending less to create more
efficient yields.
Chris Kennedy President & CEO of
Agrios stated, "We are pleased to validate the benefits of our technology
enabled approach to create a sustainable model, enabling cultivators to be
competitive, in these current volatile, compressed markets. We have a strong
foundation as we focus on our expansion efforts."
Andrew wrote a detailed explanation of
several methods of yield calculation, and the importance of yield efficiency in
a June 2019 article for the Cannabis Business Times, entitled Measuring Yield:
Why Efficiency Metrics Are Essential. Please visit the link below to view the
full article.
Therapeutic
Solutions International, Inc. (OTC: TSOI) announced today the addition of nano particle cannabidiol
to NanoMyros in the form of its proprietary product Nano Cannabidiol.
Cannabidiol
(also known as CBD), a phytocannabinoid derived from the cannabis species, is
devoid of psychoactive activity, but has analgesic, anti-inflammatory,
antineoplastic and chemopreventive activities. Upon administration, cannabidiol
(CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity
through various mechanisms.
The
addition of "Nano Cannabidiol" to NanoMyros is to inhibit
microvesicles and exosomes from being released by other cells in communication
intracellularly through the transfer of proteins. Microvesicle and exosome
release has been associated with multiple pathologies, including many cancers,
which increases drug resistance and the transfer of other pro-oncogenic
factors.
"This
final piece of this unique synergistic blend of pterostilbene, glucoraphanin,
myrosinase, and now cannabidiol is not available by any other manufacturer that
we are aware of and is built entirely on our nano products NanoStilbene and
Nano Cannabidiol," said Timothy Dixon, President, and CEO of Therapeutic
Solutions International. "We will offer the NanoMyros with and without
Nano Cannabidiol so as not to restrict anyone from the benefits of NanoPSA and
NanoMyros as stand-alone nutraceuticals."
"Preliminary
data from our collaborators indicates that this combination is effective at
decreasing both production of pathological exosomes, as well as the
responsiveness of target cells to pathological exosomes," said Thomas
Ichim, Ph.D., Board Member of TSOI.
"Specifically, we have demonstrated that subsequent to treatment of
cancer cells using the combination product, there was both a decrease in the
production of Fas ligand bearing exosomes, which are known to kill immune
cells, as well as an increased resistance of immune cells to killing by Fas
ligand bearing exosomes produced by cancer."
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use
of cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
